What is Stugeron 25mg?

Drug Stugeron 25mg is a drug of the H1 antihistamine group, used to prevent and treat symptoms such as dizziness, nausea, motion sickness...

Stugeron 25mg tablets contain the active ingredient cinnarizine 25mg and excipients just enough.
Stugeron 25mg contains cinarizin which is a derivative of piperazine with H1 antihistamine effect, anti-acetylcholine and sedative effect. Stugeron 25mg can block receptors in the vestibular terminal organs and inhibit the activation of histamine and acetylcholine secretion.

Stugeron 25mg is also a calcium antagonist. The active ingredient cinnarizine inhibits the contraction of vascular smooth muscle cells by blocking calcium channels. In addition to this direct calcium antagonist effect, cinnarizine also reduces the activity of substances with vasoconstrictor effects, such as norepinephrine and serotonin, by blocking the calcium channels operated by the receptor. Blockade of intracellular calcium influx is tissue-selective, and results in anti-vasoconstrictor properties without affecting blood pressure and heart rate.
Stugeron 25mg can further improve deficient microcirculation by increasing the deformability of red blood cells and reducing blood viscosity, helping to relieve the hypoxia of the cells. The active ingredient cinnarizine in the drug inhibits stimulation of the vestibular system, leading to suppression of nystagmus and other autonomic disorders. Acute episodes of vertigo can be prevented or reduced with stugeron 25mg.

Absorption: After oral administration, cinarizine is absorbed from the gastrointestinal tract and peak plasma concentrations are reached 2 - 4 hours. Distribution: The binding to plasma proteins of the active ingredient cinnarizine in stugeron 25mg is 91%. Metabolism: Cinnarizine is extensively metabolised primarily via CYP2D6. Elimination: After 72 hours, the drug is still excreted in the urine as metabolites. T1/2 about 3 - 6 hours. The drug stugeron 25mg is excreted mainly in the feces as unchanged drug and in the urine mainly as metabolites.

4.1. Indications Cerebral circulatory disorders: Maintenance treatment of symptoms of cerebrovascular origin, such as dizziness, tinnitus, vascular headache, irritability, memory loss, lack of concentration... Prophylaxis migraine headache . Balance Disorders: Maintenance therapy for symptoms of vestibular disorders, including dizziness, vertigo, tinnitus, nausea and vomiting, and nystagmus. Peripheral Circulatory Disorders: Stugeron 25mg is indicated for the maintenance treatment of symptoms of peripheral circulatory disorders such as Raynaud's syndrome, acrocyanosis, disruption, nutritional disorders, trophic ulcers and varicose veins. pulse , dysesthesia , nocturnal cramps , cold extremities . Motion sickness: Drug stugeron 25mg indicated in the prevention of motion sickness. 4.2. Contraindications Stugeron tablets are not contraindicated in people who are sensitive to cinarizine or any of its ingredients. Patients with porphyria are also not prescribed prescription.

6.1. How to use Stugeron 25mg tablets are used orally and should be taken after meals to limit the side effects on the stomach of the drug.
6.2. Dosage Prevention of motion sickness: Adults take one tablet of stugeron 25mg at least 30 minutes to 2 hours before traveling by train; then, repeat every 8 hours as needed. Children 5 - 12 years old, use half the adult dose. Vestibular disorders: Adults take one tablet of stugeron 25mg, 3 times daily. Children 5 - 12 years old, use half the adult dose. Cerebrovascular disorders: Adults take one tablet of stugeron 25mg, 3 times daily. Peripheral vascular disorders: Adults: 2 - 3 tablets of stugeron 5 mg x 3 times / day. The maximum dose should not exceed 225mg/day.

As with other antihistamines, stugeron tablets can cause epigastric pain. This side effect can be overcome by taking the drug after meals.
Stugeron tablets can cause drowsiness, especially at the beginning of treatment. Therefore, after taking the drug, it is necessary to avoid work that requires alertness such as driving or operating machinery. Long-term use of stugeron tablets should be avoided in the elderly, because of the potential for increased or increased extrapyramidal symptoms, sometimes associated with depression, with long-term use. Caution should be exercised when administering high doses of stugeron tablets to patients with hypotension because of the potential for a decrease in blood pressure. Although in animal studies, stugeron tablets did not show teratogenic effects as with all drugs. However, patients should only use stugeron tablets during pregnancy if the potential benefit outweighs the potential risk to the fetus. Because, taking antihistamines can cause many unwanted effects on babies. Since most antihistamines are present in milk in varying amounts, stugeron tablets should be used during lactation only when the potential benefit to the mother outweighs the potential risk to the infant.

Commonly, the frequency is greater than 1/100: on the central nervous system causes somnolence, on the digestive tract causes digestive disturbances. Rarely, the frequency is from 1/1 000 - 1/100: on the central nervous system causing headache; gastrointestinal effects such as dry mouth, weight gain and other undesirable side effects such as sweating, allergic reactions. Rarely, frequency less than 1/1000: in the central nervous system as extrapyramidal symptoms in the elderly or during long-term treatment. Cardiovascular reduces blood pressure when used in high doses. Guidelines for the management of ADR: Somnolence and gastrointestinal disturbances can be prevented by starting at a low dose and gradually increasing the dose. For those who observe worsening of the disease or develop extrapyramidal symptoms during long-term treatment in the elderly, the drug must be discontinued.

Symptoms and signs of overdosage with stugeron tablets include: altered consciousness from lethargy to stupor and coma, vomiting, or extrapyramidal symptoms, with decreased muscle tone. In a small number of young children, seizures may occur. Clinical consequences are not serious in most cases, but death has been reported following single and multiple overdoses associated with cinnarizine.
There is no specific antidote for stugeron tablet overdose. Treatment measures in case of overdose are symptomatic treatment and supportive measures. Activated charcoal can be given orally for desorption if deemed appropriate.

Stugeron tablets may interact with alcohol (central nervous system depressant), tricyclic antidepressants . In particular, when used concurrently with stugeron tablets, it is possible to increase the sedative effect of each of the above drugs or of the stugeron tablet.